← All candidates
Two insider buys in the last year — $800.0K in all.
43 filings on record.
PVLAPALVELLA THERAPEUTICS, INC.
NasdaqGM · Healthcare · $2.20B
$151.43
+0.14% today
Two insider buys in the last year — $800.0K in all.
Nothing in the last fortnight.
Price · 1Y · daily● 2 buys● 27 sells◆ 15 8-K
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
Reverse-split 1×. When a company does a reverse split, the chart rewrites its old prices to look far bigger than they really were — so the high early prices here aren't what PVLA ever actually traded at. The drop is real, but those huge old numbers aren't.
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$2.20B
Float
10.6M
74% public
Short % float
Pro
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
Director
Jenkins George M
Bought $500.0K on Feb 27 — 4,000 sh @ $125.00, held direct, 2.1% of their stake.
0 of 1 position beat the S&P
Director
Heron Elaine J
Bought $300.0K on Feb 27 — 2,400 sh @ $125.00, held direct, 5.0% of their stake.
0 of 1 position beat the S&P
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
2 filingsnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
38 more transactions on Pro →Context
Wall St
$230.53 avg target
+52.2% vs today · 15 analysts · consensus Strong Buy
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
0 of 4 quarters beat
Q2 '26−$1.52 act−$0.37
Q1 '26−$1.20 act−$0.27
Q4 '25−$1.08 act−$0.17
Q3 '25−$1.03 act−$0.18
The file stays open
43 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice